Clinical and molecular characteristics associated with response to therapeutic PD-1/PD-L1 inhibition in advanced Merkel cell carcinoma.
Ivelina SpassovaSelma UgurelLinda KubatLisa ZimmerPatrick TerheydenAnnalena MohrHannah Björn AndtbackLisa VillabonaUlrike LeiterThomas EigentlerCarmen LoquaiJessica C HasselThilo GambichlerSebastian HaferkampPeter MohrClaudia PfoehlerLucie HeinzerlingRalf GutzmerJochen S UtikalKai HornyHans-Ulrich SchildhausDaniel HabermannDaniel HoffmannDirk SchadendorfJürgen Christian BeckerPublished in: Journal for immunotherapy of cancer (2022)
among TIL, as baseline parameters associated with a favorable response to PD-1/PD-L1 ICI therapy of advanced MCC. These factors should be considered when making treatment decisions in MCC patients.